Vumerity Linked to Better Quality of Life Than Tecfidera in RRMS Trial
Vumerity (diroximel fumarate) is easier on the gastrointestinal tract than Tecfidera (dimethyl fumarate), and this translates into better quality of life for patients with relapsing-remitting multiple sclerosis (RRMS), a new analysis of EVOLVE-MS-2 trial data has found. The study, “Improved gastrointestinal profile with diroximel fumarate is…